Purchase this article with an account.
Ugo Introini, Giacinto Triolo, Giuseppe Casalino, Francesco Bandello; IRay™ treatment of Polypoidal Choroidal Vasculopathy: a Pilot Study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3786.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of stereotactic radiotherapy (IRay™, Oraya) combined with Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV) treatment.
Interventional twelve-month Pilot Study. Ten eyes of 10 patients with AMD and PCV were included. The polypoidal complex should be no closer to the optic disk than 3 mm, BCVA between 25 and 75 ETDRS letters, and axial length between 20 mm and 26 mm. At baseline, all the eyes received an intravitreal injection of Ranibizumab, followed by a single dose of 16 Gy delivered on the macular area with the IRay™ System. During monthly follow-up visits, further Ranibizumab injections were given PRN. Primary Outcomes were BCVA and Central Retinal Thickness (CRT) changes. Secondary Outcomes were mean injection number and PCV changes by means of ICGA.
At month six, mean BCVA improved from 62.8±11.6 to 66.8±13.7 ETDRS letters. Mean CRT decreased from 358.3±88.3 µm to 195.5±56 µm. Mean additional intravitreal injections were 1.9. The PCV aneurysmal bulge component was obliterated in all cases when included in the irradiation spot. No local or systemic adverse events occurred.
Our preliminary data on combined Ranibizumab and stereotactic X-ray therapy of PCV showed a mean BCVA improvement, a mean CRT decrease and aneurismal component closure. The latest results will being shown first at ARVO.
This PDF is available to Subscribers Only